Cardio Diagnostics Launches AI-Powered Epi+Gen CHD and PrecisionCHD Tests
Cardio Diagnostics Holdings is developing a suite of AI-driven clinical, population health and biopharma solutions that integrate genetic and epigenetic biomarkers for earlier detection and personalized management of preventable cardiovascular disease. The platform currently includes Epi+Gen CHD(TM) and PrecisionCHD(TM) blood-based tests aimed at identifying key risk factors in at-risk populations.
1. Broad AI-Powered Prevention Suite
Cardio Diagnostics has introduced a comprehensive suite of AI-powered solutions aimed at preventing, detecting and managing cardiovascular disease across clinical, population health and biopharma segments. The offering currently includes two blood-based assays: Epi+Gen CHD for combined epigenetic and genetic risk assessment and PrecisionCHD for personalized risk stratification.
2. Integration of Genetic and Epigenetic Biomarkers
The underlying platform integrates AI-driven analytics with genetic and epigenetic biomarkers to deliver individualized cardiovascular insights. By leveraging blood-based testing, the company targets noninvasive early detection of key risk factors.
3. Strategic Implications for Cardiovascular Care
This strategy addresses the estimated 80% of cardiovascular disease cases deemed preventable through early intervention. Widespread adoption of these tests could position Cardio Diagnostics as a leader in preventative cardiology and open new revenue opportunities.